Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $47.3 million.

  • Lucid Diagnostics' Cash & Equivalents rose 22667.54% to $47.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.3 million, marking a year-over-year increase of 22667.54%. This contributed to the annual value of $22.4 million for FY2024, which is 1832.13% up from last year.
  • As of Q3 2025, Lucid Diagnostics' Cash & Equivalents stood at $47.3 million, which was up 22667.54% from $31.1 million recorded in Q2 2025.
  • In the past 5 years, Lucid Diagnostics' Cash & Equivalents registered a high of $47.9 million during Q1 2022, and its lowest value of $14.5 million during Q3 2024.
  • Over the past 4 years, Lucid Diagnostics' median Cash & Equivalents value was $25.2 million (recorded in 2025), while the average stood at $29.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 3975.47% in 2024, then skyrocketed by 22667.54% in 2025.
  • Over the past 4 years, Lucid Diagnostics' Cash & Equivalents (Quarter) stood at $22.5 million in 2022, then dropped by 15.92% to $18.9 million in 2023, then grew by 18.32% to $22.4 million in 2024, then surged by 111.7% to $47.3 million in 2025.
  • Its Cash & Equivalents stands at $47.3 million for Q3 2025, versus $31.1 million for Q2 2025 and $25.2 million for Q1 2025.